Ajax Therapeutics Acquired by Eli Lilly | Healthcare M&A Deal

Eli Lilly has acquired Ajax Therapeutics, a pharmaceuticals business in the healthcare sector, for $2.3 billion. Eli Lilly acquisitions focus on advancing therapies for myelofibrosis and polycythemia vera, using Ajax Therapeutics’ clinical-stage drug development capabilities. Ajax Therapeutics develops hematology-focused pharmaceuticals, supporting Eli Lilly’s strategic acquisition strategy in oncology and rare blood disorders. The Eli Lilly acquisitions are structured as a platform acquisition and represent healthcare M&A led by a strategic buyer, with the Ajax Therapeutics acquisition announced at over $100M.